EXN407
/ Exonate, J&J
- LARVOL DELTA
Home
Next
Prev
1 to 7
Of
7
Go to page
1
April 15, 2024
High retinal and low systemic exposure of EXN407 eye drops in humans, a new topical therapeutic for the treatment of diabetic macular edema (DME)
(ARVO 2024)
- P1/2 | "EXN407, while having high retinal exposure, exhibits very low systemic exposure, with a maximal plasma concentration well below the levels required for efficacy (Cmax free concentration <0.001% in vitro IC50), indicating that the effect of EXN407 on retinopathy and macular thickness is due to local topical, not systemic, action."
Age-related Macular Degeneration • Diabetic Macular Edema • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration • SRPK1
April 15, 2024
A double-masked, Placebo-Controlled, Phase 1b/2a Study of EXN407 Eye Drops in Patients with Mild Center Involving Diabetic Macular Edema (DME)
(ARVO 2024)
- "Topical EXN407, BID (1.5mg/mL) was safe and well tolerated in subjects with mild, centrally-involved DME. The potential therapeutic effects of EXN407 warrant further investigation."
Clinical • P1/2 data • Age-related Macular Degeneration • Diabetic Macular Edema • Ophthalmology • SRPK1
January 10, 2023
A Study to Evaluate the Safety and Tolerability of EXN407
(clinicaltrials.gov)
- P1/2 | N=48 | Completed | Sponsor: Exonate Limited | Active, not recruiting ➔ Completed
Trial completion • Diabetes • Diabetic Macular Edema • Macular Edema • Metabolic Disorders • Ophthalmology
August 04, 2022
A Study to Evaluate the Safety and Tolerability of EXN407
(clinicaltrials.gov)
- P1/2 | N=48 | Active, not recruiting | Sponsor: Exonate Limited | Recruiting ➔ Active, not recruiting | Trial primary completion date: Mar 2022 ➔ Oct 2022
Enrollment closed • Trial primary completion date • Diabetes • Diabetic Macular Edema • Macular Edema • Metabolic Disorders • Ophthalmology
August 18, 2021
A Study to Evaluate the Safety and Tolerability of EXN407
(clinicaltrials.gov)
- P1/2; N=48; Recruiting; Sponsor: Exonate Limited; Trial primary completion date: Nov 2021 ➔ Mar 2022
Clinical • Trial primary completion date • Diabetes • Diabetic Macular Edema • Macular Edema • Metabolic Disorders • Ophthalmology
November 27, 2020
A Study to Evaluate the Safety and Tolerability of EXN407
(clinicaltrials.gov)
- P1/2; N=48; Recruiting; Sponsor: Exonate Limited; Not yet recruiting ➔ Recruiting
Clinical • Enrollment open • Diabetes • Diabetic Macular Edema • Macular Edema • Metabolic Disorders • Ophthalmology
September 25, 2020
A Study to Evaluate the Safety and Tolerability of EXN407
(clinicaltrials.gov)
- P1/2; N=48; Not yet recruiting; Sponsor: Exonate Limited
Clinical • New P1/2 trial • Diabetes • Diabetic Macular Edema • Macular Edema • Metabolic Disorders • Ophthalmology
1 to 7
Of
7
Go to page
1